At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 12 enrolled
Drug / intervention
Ixekizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Early Onset of Clinical Improvement With Ixekizumab in Patients With Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Ixekizumab for Psoriasis. Completed, enrolled 12 participants across 1 site.
Detailed Summary
To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque psoriasis and to document the same using sequential photographic images.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartApr 2015
Primary CompletionSep 2015
Study CompletionAug 2016
TodayJul 2026
First PostedMar 13, 2015
Enrollment StartApr 1, 2015
Primary CompletionSep 1, 2015
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.3 years ago
Interventions
Ixekizumabdrug
Administered SC